VP, Late Clinical DevelopmentDeciphera Pharmaceuticals, LLCWaltham, Massachusetts, United States
Disclosure information not submitted.
Paper 27 - SAFETY AND EFFICACY UPDATES FROM A PHASE 1 STUDY OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR
Thursday, November 2, 20234:00 PM – 5:30 PM